FDA approves Padcev for muscle-invasive bladder cancer
The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, as a perioperative neoadjuvant treatment and postcystectomy adjuvant treatment for ...
Dec 3, 2025
0
0
